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OBJECTIVES We sought to investigate whether statin therapy affects the association between preprocedural
C-reactive protein (CRP) levels and the risk for recurrent coronary events in patients
undergoing coronary stent implantation.
BACKGROUND Low-grade inflammation as detected by elevated CRP levels predicts the risk of recurrent
coronary events. The effect of inflammation on coronary risk may be attenuated by statin
therapy.
METHODS We investigated a potential interrelation among statin therapy, serum evidence of inflam-
mation, and the risk for recurrent coronary events in 388 consecutive patients undergoing
coronary stent implantation. Patients were grouped according to the median CRP level
(0.6 mg/dl) and to the presence of statin therapy.
RESULTS A primary combined end point event occurred significantly more frequently in patients with
elevated CRP levels without statin therapy (RR [relative risk] 2.37, 95% CI [confidence
interval] [1.3 to 4.2]). Importantly, in the presence of statin therapy, the RR for recurrent
events was significantly reduced in the patients with elevated CRP levels (RR 1.27 [0.7 to
2.1]) to about the same degree as in patients with CRP levels below 0.6 mg/dl and who did
not receive statin therapy (RR 1.1 [0.8 to 1.3]).
CONCLUSIONS Statin therapy significantly attenuates the increased risk for major adverse cardiac events in
patients with elevated CRP levels undergoing coronary stent implantation, suggesting that
statin therapy interferes with the detrimental effects of inflammation on accelerated
atherosclerotic disease progression following coronary stenting. (J Am Coll Cardiol 2001;38:
2006–12) © 2001 by the American College of Cardiology
Recent data indicate that low-grade inflammation as mea-
sured by elevated C-reactive protein (CRP) serum levels
predicts the risk of recurrent coronary events not only in
patients with myocardial infarction (MI) (1), stable or
unstable angina (2–4), but also in apparently healthy men
(5). Preprocedural CRP levels also appear to be a powerful
predictor of both early and late outcome in patients under-
going conventional balloon angioplasty (6) and stent im-
plantation (7,8), suggesting that preprocedural activation of
inflammatory cells may play a role in the modulation of
vessel wall responses to the injury induced by balloon
angioplasty. Recent data from the Cholesterol And Recur-
rent Events (CARE) trial demonstrated that in patients
with stable coronary artery disease, the effect of inflamma-
tion as measured by CRP levels on coronary risk may be
attenuated by pravastatin therapy (9), suggesting an anti-
inflammatory effect of statins in addition to the well-
established lipid-lowering properties (10–12).
Stent implantation provides a useful model to assess a
potential interrelation among serum evidence of inflamma-
tion, statin therapy and atherosclerotic disease progression,
which is primarily determined by neointimal hyperplasia.
Therefore, we investigated whether statin therapy affects the
association between preprocedural CRP levels and the risk
for recurrent coronary events in patients undergoing im-
plantation of coronary stent.
METHODS
Study population. The study population consisted of 388
consecutive patients undergoing coronary stent implanta-
tion. Indications for stenting were coronary dissection after
percutaneous transluminal coronary angioplasty (PTCA),
suboptimal results (30% residual stenosis) after PTCA,
lesions in venous bypass grafts, restenotic lesions, and
revascularization during acute MI. All patients with a stent
successfully inserted in the target lesion were included in the
analysis except for those undergoing stent implantation
during cardiogenic shock or as bridge to emergency aorto-
coronary bypass surgery. Patients with intercurrent inflam-
matory conditions, local hematoma or malignancies were
excluded. At the time of stenting, all patients were sched-
uled for a six-month follow-up angiogram, regardless of
symptomatic status. All patients gave informed consent, and
the study was approved by our institutional ethics commit-
tee. In the present study, only 118 of 388 patients (30.6%)
were overlapping with our previous study investigating the
effect of statin therapy on stent restenosis (13).
Laboratory analysis. In all patients, serum was collected
immediately before the stent implantation for measuring
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CRP levels using a commercially available kit (Turbidimet-
ric test, Boehringer Mannheim, Germany). The measuring
range is 0.3 to 24 mg/dl, with intra-assay variation coeffi-
cients ranging from 0.6% to 1.3% and interassay variation
from 1.3% to 6% at different levels of CRP. In a subset of 60
patients, the accuracy of the turbidimetric CRP measure-
ment was validated against the latex-enhanced high-
sensitivity CRP assay (Dade Behring, Germany). Compar-
ison of the two assays not only revealed a close correlation
(r 0.82, p 0.001), but, more importantly, demonstrated
that CRP levels 0.5 mg/dl can be reliably detected using
the turbidimetric test. Serum cholesterol levels were mea-
sured before the initial angioplasty as well as at follow-up.
Stent implantation procedure. Stent implantation of four
different types of slotted-tube stents (Palmaz-Schatz,
Jomed, Inflow, and Multilink stents) using high-pressure
balloons was performed as previously described (8,13). All
patients were on chronic aspirin (100 mg/day) therapy or
received 500 mg of aspirin intravenously before the proce-
dure. Patients received 10,000 to 15,000 U heparin after
insertion of the arterial sheath and, if necessary, a repeat
bolus of 5,000 U was administered to maintain the activated
clotting time 250 s. Glycoprotein IIb/IIIa inhibitors were
administered in 34 patients (8.7%).
Quantitative coronary angiography. Quantitative mea-
surements were performed by fully computerized quantita-
tive angiography (CMS, Medis, Nuenen, Netherlands) to
obtain minimal luminal diameter (MLD), reference diam-
eter and percent diameter stenosis. Lesions were classified
according to the modified American College of Cardiology/
American Heart Association criteria (14). Analyses were
performed per patient (only one randomly selected lesion
per subject). Stent restenosis was defined as a dichotomous
outcome (50% diameter stenosis within the stent or stents
at follow-up). Acute gain was defined as the difference
between MLD after stent implantation and the MLD
before PTCA. Late loss was defined as the difference
between the MLD after stent insertion and the MLD at
follow-up, and net gain was defined as the difference
between acute gain and late loss.
Postprocedure medication protocol. Either ticlopidine
250 to 500 mg/day (n  343) or clopidogrel 75 mg/day
(n  45) was given for four weeks and aspirin 100 mg/day
indefinitely.
Most patients (176; 70.7%) received simvastatin; 16
(6.4%) received lovastatin, 42 (16.9%) received atorvastatin,
6 (2.4%) received fluvastatin, 6 (2.4%) received pravastatin
and 3 (1.2%) received cerivastatin, respectively. Forty-five of
388 (11.6%) patients were on statin therapy prior to the
stent implantation procedure and were continued on statin
therapy. In 204 patients, statin therapy was initiated the day
after stent insertion and continued throughout the study
period.
Definition of events and follow-up. The primary com-
bined end point was death due to cardiac causes, MI related
to the target vessel or repeat intervention of the stented
vessel (PTCA or aortocoronary bypass surgery). The diag-
nosis of MI was based on anginal symptoms and typical
electrocardiographic changes plus an increase in creatine
kinase  twice the upper limit of normal with a concomi-
tant rise in the MB isoenzyme or a positive troponin T test.
Clinical six-month follow-up was available in all 388 pa-
tients. Follow-up coronary angiograms to evaluate angio-
graphic stent restenosis rates were performed in 337 of 378
(89.1%) patients eligible for planned reangiography between
four to six months after stent placement. Target vessel
revascularization (TVR) was defined as repeat intervention
of restenotic lesions, which included the target site of the
stent implantation or proximal and distal in the same major
coronary artery. The TVR was driven by the presence of
ischemia indicated either by the recurrence of typical symp-
toms of angina or a positive exercise stress test.
Data and statistical analysis. Data are expressed as per-
centages for discrete variables and as mean  SD for
continuous variables. Continuous variables were compared
by means of the Student t test or the Mann-Whitney U test.
Multiple comparisons were performed by either the
Kruskal-Wallis test or analysis of variance with the Bonfer-
roni correction. A multivariate logistic regression analysis
was performed to examine independent predictors of resten-
osis using SPSS version 9.0, by entering the following
variables: CRP levels 0.6 mg/dl, statin therapy and the
previously described classical risk factors for restenosis such
as MLD, number of stents implanted, reference vessel size,
diabetes mellitus and cholesterol levels. A forward entry
stepping algorithm was used with the entry criteria proba-
bility of F (0.05). An additional logistic regression analysis
and also a multivariate Cox regression analysis were per-
formed, analyzing the predictability of the same variables on
clinical events. Chi-square analysis or logistic regression was
used to estimate relative risk (RR) and 95% confidence
intervals (CIs). Long-term clinical adverse events were
compared by the Kruskal-Wallis test for multiple compar-
isons or Kaplan-Meier survival curves, and the correspond-
ing p value was obtained from the log-rank test. Statistical
significance was assumed at p  0.05.
Abbreviations and Acronyms
CI  confidence interval
CARE  Cholesterol And Recurrent Events trial
CRP  C-reactive protein
MI  myocardial infarction
MIRACL  Myocardial Ischemia Reduction with
Aggressive Cholesterol Lowering trial
MLD  minimal lumen diameter
PTCA  percutaneous transluminal coronary
angioplasty
RR  relative risk
TVR  target vessel revascularization
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RESULTS
Baseline characteristics. The baseline clinical, angio-
graphic, and procedural characteristics of the study popula-
tion are summarized in Table 1. Except for cholesterol
levels, patients with or without statin therapy did not differ
in any clinical or procedural variable. The CRP levels
ranged from 0.0 to 8.0 mg/dl, with a median value of
0.6 mg/dl.
Effects of statin therapy. To investigate for evidence of an
interrelation between inflammation and statin therapy, the
patients were divided into four groups on the basis of the
presence or absence of elevated CRP levels (above median
value) and on the presence or absence of statin therapy. As
shown in Figure 1, a significantly increased risk for recurrent
adverse coronary events existed across the four groups of
patients (p  0.003). Compared with the lowest-risk
group (patients with CRP levels below the median level
receiving statin therapy), patients with elevated CRP
levels without statin therapy experienced the highest risk
of recurrent coronary events (RR 2.37, 95% CI [1.3 to
4.2]). Importantly, in the presence of statin therapy, the
RR for recurrent events was significantly reduced in
patients with elevated CRP levels (RR 1.27 [0.7 to 2.1])
to about the same degree as in patients with CRP levels
below 0.6 mg/dl and who did not receive statin therapy
(RR 1.1 [0.8 to 1.3]).
Table 2 summarizes the individual clinical end points
combined for the primary end point analysis as illustrated by
Kaplan-Meier survival curves (Fig. 2). Myocardial infarc-
tions that were not related to the target vessel occurred in
three patients with elevated CRP levels receiving statin
therapy. The effect of lipid lowering was essentially identical
in the two groups of patients receiving statin treatment
(30.8  32 mg/dl vs. 34.3  40 mg/dl, p  0.6), whereas
lipid levels remained unchanged in the no-statin groups.
Angiographic follow-up. Table 3 summarizes the quanti-
tative angiographic data obtained at baseline and at
follow-up angiography. Patients with elevated CRP levels
had significantly higher restenosis rates. However, statin
therapy reduced the excess risk for restenosis development
especially in patients with elevated CRP levels (34.9% vs.
50%, p 0.04, respectively). When the categorical criterion
of 50% diameter stenosis at follow-up was used to assess
restenosis development, the difference among the four
groups (treated or nontreated) was highly significant (p 
0.005).
Table 1. Baseline Clinical and Procedural Characteristics of the Study Population
Characteristic
No Statin
(n  139 [35.8%])
Statin
(n  249 [64.2%]) p Value
Age (median, yrs) 64 61
Women 27 (19.4%) 55 (22.1%) 0.5
Ejection fraction (%) 50  11 51  11 0.3
Acute coronary syndromes 72 (51.7%) 133 (53.4%) 0.2
Current cigarette smoking 36 (26.1%) 70 (28.1%) 0.2
Insulin-dependent diabetes 19 (13.6%) 25 (10%) 0.2
Systemic hypertension 84 (60.4%) 151 (60.1%) 0.9
Previous myocardial infarction 55 (39.6%) 92 (37%) 0.3
History of CABG 19 (13.6%) 35 (14%) 0.5
Baseline cholesterol 204  36 233  42 0.001
Baseline low-density lipoprotein 123  33 146  36 0.001
Baseline high-density lipoprotein 48  15 49  12 0.6
Triglycerides 161  92 178  83 0.09
CRP level (mg/dl) 1.3  1.6 1.2  1.5 0.4
No. of diseased vessels
1 40 (28.7%) 76 (30.5%)
2 41 (29.5%) 75 (30.1%) 0.8
3 58 (41.8%) 98 (39.4%)
Lesion type (ACC-AHA)
A 0 (0%) 2 (0.8%)
B 108 (77.7%) 191 (76.8%) 0.3
C 31 (22.3%) 56 (22.4%)
Treated vessel
LAD 57 (41%) 124 (49.8%)
LCX 26 (18.7%) 31 (12.5%) 0.2
RCA 50 (36%) 77 (30.9%)
SVG 6 (4.3%) 17 (6.8%)
Maximum inflation pressure (atm) 14  2 14  2 0.3
Ballon/vessel ratio 1.06  0.1 1.05  0.1 0.3
Cumulative stent length (mm) 21  12 22  13 0.6
ACC-AHA  American College of Cardiology–American Heart Association lesion classification; CABG  coronary artery
bypass graft; CRP C-reactive protein; LAD left anterior descending; LCX left circumflex; RCA right coronary artery;
SVG  saphenous vein graft.
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Multivariate analysis. RESTENOSIS. Logistic regression
analysis revealed that statin therapy (p  0.04), elevated
CRP levels (p  0.02), MLD post-stent implantation (p 
0.02) and the number of stents implanted (p  0.03), but
not reference segment diameter (p  0.6), diabetes (p 
0.15) or total serum cholesterol levels (p  0.15), were
independent predictors of stent restenosis.
CLINICAL EVENTS. On logistic regression analysis, statin
therapy (p  0.03), MLD post-stent (p  0.04), and stent
length (p  0.01), but not reference vessel size (p  0.5),
cholesterol levels (p  0.1), and diabetes (p  0.2) were
independently associated with the occurrence of a primary
clinical end point. Furthermore, when a multivariate Cox
regression analysis was performed, only statin therapy (p 
0.04), MLD post-stent (p  0.04) and stent length (p 
0.02) remained independent predictors of an adverse clinical
outcome. Importantly, in the presence of statin therapy, an
elevated CRP level was no longer an independent predictor
for subsequent adverse coronary events.
DISCUSSION
Major findings. The results of the present study demon-
strate that statin therapy abrogates the increased risk for
adverse cardiac events associated with elevated CRP serum
Figure 1. Relative risks for primary combined end point events (death, myocardial infarction, target vessel revascularization) within six-month follow-up
according to the presence or absence of elevated C-reactive protein (CRP) levels (above median value 0.6 mg/dl) or presence or absence of statin treatment
in patients following coronary stent implantation.
Table 2. Clinical Events at Six-Month Clinical Follow-Up
Six-months (n  388)
CRP < 0.6 mg/dl (n  181) CRP > 0.6 mg/dl (n  207)
No Statin
(n  56)
Statin
(n  125) p Value
No Statin
(n  83)
Statin
(n  124) p Value
Subacute stent thrombosis 0 (0%) 0 (0%) 0.9 4 (4.8%) 4 (3.2%) 0.5 (0.056)*
MI (target vessel) 0 (0%) 2 (1.6%) 0.4 6 (7.2%) 6 (4.8%) 0.4 (0.1)*
Death (cardiac) 2 (3.5%) 0 (0%) 0.2 5 (6.0%) 3 (2.4%) 0.3 (0.1)*
TVR 16 (29.6%) 34 (27.2%) 0.8 32 (38.6%) 36 (29.0%) 0.17 (0.2)*
Primary combined endpoint
(Target vessel MI, death, TVR)
18 (32.1%) 34 (27.2%) 0.4 39 (47%) 40 (32.3%) 0.03 (0.028)*
*p Value obtained from Kruskal-Wallis test for multiple comparisons (log-rank test p  0.012); myocardial infarction (MI) end point consists of nonfatal and fatal MI.
CRP  C-reactive protein; TVR  target vessel revascularization.
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levels indicative of low-grade inflammation in patients
undergoing coronary stent implantation. The data of the
present study are highly reminiscent of a previously pub-
lished report demonstrating that pravastatin attenuated the
increased risk of recurrent coronary events among stable
patients with a prior history of MI but with elevated CRP
serum levels (9). However, in the present study, the bene-
ficial effects of statin therapy were observed within a
Figure 2. Cumulative survival curves for primary combined end point events (death, myocardial infarction [MI], target vessel revascularization) within
six-month follow-up according to the presence or absence of elevated C-reactive protein (CRP) levels (above median value 0.6 mg/dl) or presence and
absence of statin treatment in patients following coronary stent implantation. The p value was obtained from the log-rank test.
Table 3. Quantitative Coronary Angiographic Analysis
CRP < 0.6 mg/dl (n  181) CRP > 0.6 mg/dl (n  207)
No Statin
(n  56)
Statin
(n  125) p Value
No Statin
(n  83)
Statin
(n  124) p Value
Pre-PTCA
Reference diameter (mm) 3.0  0.6 2.9  0.5 0.4 2.97  0.6 3.1  0.6 0.3
MLD (mm) 0.81  0.6 0.82  0.6 0.8 0.7  0.6 0.75  0.6 0.6
Percent stenosis 72  17 72  17 0.7 77  17 76  17 0.8
Post-stent
Reference diameter (mm) 3.0  0.5 3.0  0.5 0.6 3.0  0.5 3.0  0.5 0.4
MLD (mm) 2.6  0.5 2.57  0.5 0.7 2.6  0.5 2.65  0.5 0.3
Percent stenosis 14  12 15  11 0.7 15  13 15  11 0.9
Acute gain (mm) 1.9  0.6 1.9  0.7 0.4 2.0  0.7 2.0  0.7 0.9
No Statin
(n  44)
Statin
(n  114) p Value
No Statin
(n  66)
Statin
(n  113) p Value
Follow-up (n  337)
Reference diameter (mm) 2.96  0.5 2.87  0.85 0.4 3.0  0.6 3.0  0.6 0.6
MLD (mm) 1.7  0.8 1.8  0.8 0.4 1.57  0.95 1.84  0.87 0.07 (0.05)*
% stenosis 42  24 36  23 0.2 50  26 40  24 0.024 (0.008)*
Late loss 0.86  0.7 0.7  0.7 0.3 0.99  0.88 0.63  0.8 0.048 (0.06)*
Restenosis rate 50% 16 (38.0%) 25 (21.9%) 0.07 33 (50%) 39 (34.5%) 0.04 (0.003)†
*p Value from ANOVA. †p Value from Kruskal-Wallis test for multiple comparisons.
CRP  C-reactive protein; MLD  minimal lumen diameter; PTCA  percutaneous transluminal coronary angioplasty.
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six-month follow-up period, whereas in the CARE
study—as in the other lipid-lowering trials—approximately
two years of treatment were required before a significant
reduction in cardiovascular events could be discerned
(11,15–17).
Recent data of the Myocardial Ischemia Reduction with
Aggressive Cholesterol Lowering (MIRACL) trial (18)
indicated that the beneficial effects of statin therapy also
extend to patients experiencing an acute ischemic coronary
event. However, in the MIRACL study a conservative
treatment strategy for patients with acute coronary syn-
dromes was anticipated (18). Results of the present study
now indicate the potential role of statins to modify clinical
outcome further in patients undergoing an aggressive inter-
ventional approach with coronary stent implantation.
Pathophysiologic mechanisms of statin effects. Systemic
inflammatory reactions play a pivotal role for neointima
formation within stents (19). Patients with elevated CRP
serum levels exhibit a marked hyperresponsiveness of the
inflammatory system to nonspecific stimuli like vessel wall
traumatization by balloon angioplasty (20). In addition,
elevated CRP levels are associated with a dramatically
impaired endothelial vasodilator function (21). Finally, ac-
tivation of inflammatory cells and cytokines can aggravate
local thrombotic complications by increasing procoagulant
or platelet activity or promoting thrombin generation (22).
Thus, preprocedural activation of inflammatory cells ap-
pears to profoundly modify the vessel wall response to injury
(23–25), leading to a significant increase in clinical compli-
cations and restenosis rates following coronary stent implan-
tation, as observed in the present study.
Conversely, statins have been shown to exert beneficial
physiologic effects within weeks. In conjunction with low-
ering lipid levels, statins have been shown to reduce vascular
inflammation (26), improve endothelial function (27) and
reduce platelet aggregability and thrombus formation (28).
Thus, statins appear to interfere specifically with the patho-
physiological mechanisms implicated in the dramatically
accelerated progression of atherosclerotic disease in im-
planted stents in patients with low-grade systemic inflam-
mation.
Study limitations. The lack of a placebo-controlled, ran-
domized design might be regarded as a major limitation of
the present study. However, statin therapy was initiated
based on elevated serum cholesterol levels, but not on CRP
serum levels. In fact, preprocedural CRP levels did not differ
between patients with or without statin therapy. In addition,
CRP levels did not correlate with serum cholesterol levels.
C-reactive protein levels were not known either to the
physician in charge of initiating statin therapy, nor to the
operator at the time of reangiography, nor to the technician
analyzing the coronary angiograms. Thus, it is highly
unlikely that a selection bias might have contributed to the
observed outcome.
Finally, glycoprotein IIb/IIIa receptor blockers were in-
frequently used in this patient population. Hence, we
cannot comment on potentially additional effects of statins
in patients with glycoprotein IIb/IIIa-receptor blockade.
Conclusions. Results of the present study demonstrate that
statin therapy significantly attenuates the increased risk for
major adverse cardiac events in patients with elevated CRP
levels undergoing coronary stent implantation, suggesting
that statin therapy interferes with the detrimental effects of
inflammation on accelerated atherosclerotic disease progres-
sion following coronary stenting. Elevated CRP levels
appear to be a powerful tool to target statin therapy to
patients who are exposed to the highest risk for ischemic
coronary events following coronary stent implantation.
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